Recursion Pharma Partners with NVIDIA for AI Drug Discovery

Ticker: RXRX · Form: 8-K · Filed: Jun 24, 2024 · CIK: 1601830

Recursion Pharmaceuticals, Inc. 8-K Filing Summary
FieldDetail
CompanyRecursion Pharmaceuticals, Inc. (RXRX)
Form Type8-K
Filed DateJun 24, 2024
Risk Levelmedium
Pages2
Reading Time2 min
Key Dollar Amounts$0.00001
Sentimentneutral

Sentiment: neutral

Topics: collaboration, AI, drug-discovery

Related Tickers: NVDA

TL;DR

Recursion is teaming up with NVIDIA to supercharge drug discovery with AI.

AI Summary

Recursion Pharmaceuticals, Inc. announced on June 24, 2024, that it entered into a strategic collaboration with NVIDIA Corporation. This collaboration aims to accelerate drug discovery and development by leveraging NVIDIA's advanced AI and computing technologies. The partnership will focus on expanding Recursion's drug discovery platform and developing new AI models for biological research.

Why It Matters

This collaboration could significantly speed up the identification and development of new drugs by combining Recursion's biological data with NVIDIA's cutting-edge AI capabilities.

Risk Assessment

Risk Level: medium — While the partnership is promising, the success of drug discovery is inherently uncertain and depends on many factors beyond AI capabilities.

Key Players & Entities

  • Recursion Pharmaceuticals, Inc. (company) — Registrant
  • NVIDIA Corporation (company) — Strategic Partner
  • June 24, 2024 (date) — Date of earliest event reported
  • RXRX (ticker) — Class A Common Stock Trading Symbol

FAQ

What is the primary goal of the collaboration between Recursion Pharmaceuticals and NVIDIA?

The primary goal is to accelerate drug discovery and development by leveraging NVIDIA's AI and computing technologies to expand Recursion's drug discovery platform and develop new AI models for biological research.

When was the earliest event reported in this 8-K filing?

The earliest event reported was on June 24, 2024.

What is the trading symbol for Recursion Pharmaceuticals' Class A Common Stock?

The trading symbol is RXRX.

On which stock exchange is Recursion Pharmaceuticals' Class A Common Stock traded?

Recursion Pharmaceuticals' Class A Common Stock is traded on the Nasdaq Global Select Market.

What is the principal executive office address for Recursion Pharmaceuticals, Inc.?

The principal executive offices are located at 41 S Rio Grande Street, Salt Lake City, UT 84101.

Filing Stats: 586 words · 2 min read · ~2 pages · Grade level 9.6 · Accepted 2024-06-24 08:02:25

Key Financial Figures

  • $0.00001 — stered Class A Common Stock, par value $0.00001 per share RXRX Nasdaq Global Select Mar

Filing Documents

01. Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure. On June 24, 2024, Recursion Pharmaceuticals, Inc. (the "Company") issued a press release related to announcements made during its Download Day investor meeting. The press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated into this Item 7.01 by reference. Also on June 24, 2024, the Company released an updated investor presentation. The investor presentation will be used at its Download Day investor meeting and from time to time in meetings with investors. A copy of the presentation is attached hereto as Exhibit 99.2 to this Current Report on Form 8-K and incorporated into this Item 7.01 by reference. The information furnished in this Item 7.01 (including Exhibit 99.1 and 99.2), shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Press Release of Recursion Pharmaceuticals, Inc. dated June 24, 2024. 99.2 Investor Presentation of Recursion Pharmaceuticals, Inc. dated June 24, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized on June 24, 2024. RECURSION PHARMACEUTICALS, INC. By: /s/ Michael Secora Michael Secora Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.